Stock Analiz

BeOne Medicines Ltd. (ONC) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

BeOne Medicines’s revenue went from $1M in fiscal 2016 to $5.3B in fiscal 2025, growth of about 157.6% a year.

Net income in fiscal 2025 was $287M, a net margin of 5.4%; the highest of the period.

Over the twelve months to September 30, 2026, revenue was $6.6B and net income $916M.

Free cash flow was $942M in fiscal 2025 and positive in 1 of the 10 years shown.

The diluted share count rose 265% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2016: $1M162017: $238M172018: $198M182019: $428M192020: $309M202021: $1.2B212022: $1.4B222023: $2.5B232024: $3.8B242025: $5.3B25$5.3B
Net income
2016: -$119M162017: -$93M172018: -$674M182019: -$949M192020: -$1.6B202021: -$1.5B212022: -$2.0B222023: -$882M232024: -$645M242025: $287M25$287M
Free cash flow
2016: -$113M162017: -$34M172018: -$618M182019: -$840M192020: -$1.4B202021: -$1.6B212022: -$1.8B222023: -$1.7B232024: -$633M242025: $942M25$942M
EPS (diluted)
2016: $-0.30162017: $-0.16172018: $-0.93182019: $-1.22192020: $-1.50202021: $-1.21212022: $-1.49222023: $-0.65232024: $-0.47242025: $0.1925$0.19

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$6.6B$5.3B$3.8B$2.5B$1.4B$1.2B$309M$428M$198M$238M$1M
Gross profit$5.9B$4.7B$3.2B$2.1B$1.1B$1.0B$238M$357M$170M$233M$1M
Operating income$1.2B$447M-$568M-$1.2B-$1.8B-$1.4B-$1.7B-$960M-$706M-$98M-$117M
Net income$916M$287M-$645M-$882M-$2.0B-$1.5B-$1.6B-$949M-$674M-$93M-$119M
EPS (diluted)$7.88$0.19$-0.47$-0.65$-1.49$-1.21$-1.50$-1.22$-0.93$-0.16$-0.30
R&D$2.4B$2.1B$2.0B$1.8B$1.6B$1.5B$1.3B$927M$679M$269M$98M
Revenue growth—+40.2%+55.0%+73.7%+20.4%+280.8%−27.9%+116.0%−16.9%+22179.2%−87.9%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$1.6B$1.1B-$141M-$1.2B-$1.5B-$1.3B-$1.3B-$750M-$548M$13M-$90M
Capital spending-$141M-$186M-$493M-$562M-$325M-$263M-$118M-$90M-$70M-$46M-$24M
Free cash flow$1.4B$942M-$633M-$1.7B-$1.8B-$1.6B-$1.4B-$840M-$618M-$34M-$113M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks———————————
Stock-based pay$517M$511M$442M$368M$303M$241M$183M$134M$87M$43M$11M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$4.5B$2.6B$3.2B$4.5B$6.6B$4.7B$983M$1.8B$838M$368M
Debt—$1.1B$1.1B$930M$597M$695M$562M$120M$77M$18M$17M
Equity—$4.4B$3.3B$3.5B$4.4B$6.1B$3.9B$962M$1.7B$670M$353M
Total assets—$8.2B$5.9B$5.8B$6.4B$8.5B$5.6B$1.6B$2.2B$1.0B$406M
Shares (diluted)116M1.47B1.37B1.36B1.34B1.21B1.09B781M721M543M404M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin89.4%87.5%84.4%84.5%79.8%86.0%77.1%83.4%85.5%97.9%100.0%
Operating margin17.8%8.4%-14.9%-49.1%-126.4%-122.3%-536.7%-224.2%-356.1%-41.3%-10940.2%
Net margin13.9%5.4%-16.9%-35.9%-141.5%-123.9%-526.1%-221.5%-339.9%-39.1%-11141.8%
FCF margin21.9%17.6%-16.6%-69.9%-128.7%-132.8%-453.6%-196.1%-311.8%-14.1%-10562.1%
ROIC—5.6%-10.2%-21.4%-28.4%-16.7%-29.5%-70.1%-38.0%-11.3%-25.0%
ROE—6.6%-19.4%-24.9%-45.7%-23.8%-42.0%-98.6%-38.7%-13.9%-33.8%

Frequently asked questions

What is BeOne Medicines’s annual revenue?

$5.3B in fiscal 2025 and $6.6B over the twelve months to September 30, 2026.

How much profit does BeOne Medicines make?

Net income was $287M in fiscal 2025 (net margin 5.4%).

Is BeOne Medicines’s revenue growing?

Yes: revenue rose 40.2% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.